Combination therapy of boron neutron capture therapy and bevacizumab for recurrent glioma with poor prognosis
Phase 2
- Conditions
- recurrent glioma with poor prognosis
- Registration Number
- JPRN-jRCTs051180218
- Lead Sponsor
- Miyatake Shin-Ichi
- Brief Summary
Three cases out of 4 were dead and 1 case is still alive at the date of censored. BNCT and additive bevacizumab could prolong all 4 recurrent, with poor-prognoses glioma cases with the reference with RPA classification. (Original RPA class 7 cases showed 4.9 months as median survival after recurrence). No brain radiation necrosis occurred with bevacizumab treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 4
Inclusion Criteria
See the attached file.
Exclusion Criteria
See the attached file.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method